Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laser companies set to battle for angina market

This article was originally published in Clinica

Executive Summary

The number of transmyocardial revascularisation (TMR) devices on the US market doubled last week when the FDA approved the Eclipse Surgical Technologies' holmium laser-based system. The prompt final approval came after the device won strong backing from the FDA review panel in October 1998, for its effectiveness in reducing angina pain in patients with severe coronary artery disease (see Clinica No 832, p 15). The company's share price rose 21% to $13.625 on the day of the announcement.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel